<DOC>
	<DOCNO>NCT01540136</DOCNO>
	<brief_summary>This Phase III trial study effectiveness nedaplatin versus cisplatin IMRT chemoradiotherapy treat patient locoregionally advanced nasopharyngeal carcinoma .</brief_summary>
	<brief_title>Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>Nasopharyngeal carcinoma ( NPC ) endemic Southern China Southeast Asia . Several prospective randomize trial demonstrate concurrent chemoradiotherapy superior radiotherapy alone treatment locoregionally advance NPC . Cisplatin-based chemotherapy show high response rate NPC noncisplatin regimen . However , patient ' compliance unsatisfactory obvious gastrointestinal toxicity cisplatin . Nedaplatin new second generation platinum slight gastrointestinal reaction . Our trial order study effectiveness nedaplatin cisplatin intensity-modulated radiation therapy ( IMRT ) chemoradiotherapy treat patient locoregionally advanced NPC .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Nedaplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Patients newly histologically confirm nonkeratinizing nasopharyngeal carcinoma , include WHO II III Original clinical stag T14N13 T34N0（according 7th AJCC edition） No evidence distant metastasis ( M0 ) Male pregnant female Age 1865 WBC ≥ 4,000/mm3 PLT ≥ 100,000/mm3 With normal liver function test ( ALT、AST ≤ 2.5×ULN ) With normal renal function test ( Creatinine ≤ 1.5×ULN ) Satisfactory performance status : Karnofsky scale ( KPS ) &gt; 70 Without radiotherapy chemotherapy Patients must give sign informed consent Patients evidence relapse distant metastasis The presence uncontrolled lifethreatening illness Receiving way anticancer therapy Receiving radiotherapy chemotherapy Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>